Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 10/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25405520 | 1.00 | GLP1R (0.41) | GLP1RKCNH2KDM4EALDH1A1HPGD | |
| SCHEMBL25405514 | 1.00 | GLP1R (0.41) | GLP1RKCNH2KDM4EALDH1A1HPGD | |
| Tromethamine SCHEMBL30608942 | 0.91 | GLP1R (0.37) | GLP1RKCNH2KDM4EALDH1A1HPGD | |
| SCHEMBL29480771 | 0.90 | TRPA1 (0.40) | GLP1RKDM4EALDH1A1HPGDTSHR | |
| SCHEMBL29558931 | 0.86 | ALDH1A1 (0.40) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL29079760 | 0.86 | ALDH1A1 (0.40) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL29079758 | 0.86 | ALDH1A1 (0.40) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL25435833 | 0.84 | CYP1A2 (0.40) | KCNH2KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL30124865 | 0.84 | CYP1A2 (0.40) | KCNH2KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL29668753 | 0.84 | CYP1A2 (0.40) | KCNH2KDM4EALDH1A1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114728939-B | GLP-1 receptor agonists and uses thereof | 日东制药株式会社 | 2023-12-08 | — | — | CN | claimed |
| CN-114728939-A | GLP-1 receptor agonists and uses thereof | 日东制药株式会社 | 2022-07-08 | — | — | CN | claimed |
| CN-114728940-A | GLP-1 receptor agonists and uses thereof | 日东制药株式会社 | 2022-07-08 | — | — | CN | claimed |
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | MINDRANK AI LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC (CN) | 2026-02-05 | — | — | US | disclosed |
| US-12497384-B2 | Aryl ether-substituted heterocyclic compounds as GLP1R agonists | MINDRANK AI LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-20250304553-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| US-20250282757-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2025-09-11 | — | — | US | disclosed |
| US-20250235460-A1 | COMBINATION THERAPY USING GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONIST COMPOUNDS AND GLP-1 RECEPTOR AGONIST COMPOUNDS | PFIZER INC. (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| US-20250042883-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2025-02-06 | — | — | US | disclosed |
| WO-2022246019-A1 | MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2022-11-24 | — | — | WO | disclosed |
| CN-114907351-A | Tricyclic GLP-1 receptor agonists and uses thereof | 杭州中美华东制药有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-114728939-A | GLP-1 receptor agonists and uses thereof | 日东制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| CN-114716423-A | 5, 6-dihydro-1, 2, 4-triazines and their pharmaceutical use as GLP-1 receptor agonists | 中国科学院上海药物研究所 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728940-A | GLP-1 receptor agonists and uses thereof | 日东制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| CN-113480534-B | Benzimidazole or azabenzimidazole-6-carboxylic acid compounds and application thereof | 广州必贝特医药股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| WO-2022042691-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| EP-3953344-A1 | GLP-IR AGONISTS AND USES THEREOF | Qilu Regor Therapeutics Inc. (CN) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, IAPP | GLP1R 1/4885KCNH2 2073/4885KDM4E 2588/4885 |
| US-12497384-B2 | Aryl ether-substituted heterocyclic compounds as GLP1R agonists | GLP1R, GIPR, GCGR | GLP1R 1/4885KCNH2 779/4885KDM4E 2089/4885 |
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | GLP1R, GIPR, GCGR | GLP1R 1/4885KCNH2 437/4885KDM4E 1713/4885 |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | GLP1R 1/4885KCNH2 1883/4885KDM4E 3611/4885 |
| US-20250304553-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | GLP1R 1/4885KCNH2 924/4885KDM4E 2390/4885 |
| US-20250282757-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | GLP1R 1/4885KCNH2 705/4885KDM4E 2046/4885 |
| US-20250042883-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | GLP1R 1/4885KCNH2 3024/4885KDM4E 3200/4885 |
| US-20250235460-A1 | COMBINATION THERAPY USING GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONIST COMPOUNDS AND GLP-1 RECEPTOR AGONIST COMPOUNDS | GLP1R, GIPR, GPR119 | GLP1R 1/4885KCNH2 2947/4885KDM4E 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.